ERBB3 and head and neck squamous cell carcinoma: Seribantumab (MM-121 or SAR256212) is a fully human monoclonal antibody targeting HER3.[109] In preclinical models of lung cancer and HNSCC, seribantumab decreased HER3 phosphorylation.[109, 110] A preclinical animal model of ovarian cancer treated with seribantumab also showed decreased tumor growth.[111]